Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors
Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer
Gleevec Approval Sets Record For FDA Review: 73 Days
Advances Found In Treatment Of Aerodigestive Cancers
Silicone Implants Not Linked To Increased Risk Of Death
B-14 Trial: No Advantage To 10 Years Of Tamoxifen
NCI-Approved Clinical Trials Listed For April 2001
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO